STOK
NASDAQ · Biotechnology
Stoke Therapeutics Inc
$28.05
-0.38 (-1.34%)
Open$28.80
Previous Close$28.43
Day High$28.80
Day Low$27.75
52W High$40.22
52W Low$20.32
Volume—
Avg Volume672.5K
Market Cap1.87B
P/E Ratio—
EPS$-3.36
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+78.9% upside
Current
$28.05
$28.05
Target
$50.17
$50.17
$29.72
$50.17 avg
$68.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 208.29M | 323.22M | 315.22M |
| Net Income | -7,778,658 | -37,471,003 | -43,595,472 |
| Profit Margin | -3.7% | -11.6% | -13.8% |
| EBITDA | -21,255,870 | -52,091,948 | -53,358,586 |
| Free Cash Flow | — | -52,998,459 | -42,607,892 |
| Rev Growth | +145.9% | +14.4% | -1.8% |
| Debt/Equity | — | 0.58 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |